Evidence map›Paper›PMID 42380457›Full record

ArticleScientific reports2026

Assessment of anti-VEGF intravitreal injection effects on murine neonatal Schlemm's canal morphology.

Gabriella D Hartman, Amirhesam Afsharpour, Sean M Martin, Dawei Qu, Stuart W Tompson, Kamakshi Sishtla, Kristina N Whisenhunt, Anbukkarasi Muniyandi, Timothy W Corson, Terri L Young

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gabriella D HartmanDepartment of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, USA.
Amirhesam AfsharpourLeslie Dan Faculty of Pharmacy, University of Toronto, 144 College St, Toronto, ON, M5S 3M2, Canada.
Sean M MartinDepartment of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, 2828 Marshall Ct, Ste 200, Madison, WI, USA.
Dawei QuThe Center for Phenogenomics, Toronto, ON, Canada.
Stuart W TompsonDepartment of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, 2828 Marshall Ct, Ste 200, Madison, WI, USA.
Kamakshi SishtlaDepartment of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, USA.
Kristina N WhisenhuntDepartment of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, 2828 Marshall Ct, Ste 200, Madison, WI, USA.
Anbukkarasi MuniyandiDepartment of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, USA.
Timothy W CorsonDepartment of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, USA. tim.corson@utoronto.ca.ORCID https://orcid.org/0000-0002-1402-7875
Terri L YoungDepartment of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, 2828 Marshall Ct, Ste 200, Madison, WI, USA. tyoung6@wisc.edu.

Funding

UW Vision Research Core - Administrative CoreP30EY016665 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI AKIHIRO IKEDA · 2005 to 2026
$12.6M
Ferrochelatase as a mediator of ocular angiogenesisR01EY025641 · NEI · UNIVERSITY OF TORONTO · PI Timothy W Corson · 2016 to 2026
$3.5M
Single cell transcriptome profiling of aqueous humor outflow development for discovery of novel childhood glaucoma genesR21EY034251 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI TOMPSON, STUART WILLIAM JAMES · 2022 to 2023
$428k
Ref-1 in Retinal NeovascularizationF31EY035171 · NEI · INDIANA UNIVERSITY INDIANAPOLIS · PI HARTMAN, GABRIELLA · 2023 to 2024
$69k
Natural Sciences and Engineering Research Council of Canada RGPIN-2025-04563NEI NIH HHS F31 EY035171NEI NIH HHS P30 EY016665NEI NIH HHS R01 EY025641NEI NIH HHS R21 EY034251
6 · The paper itself

Abstract

Anti-VEGF intravitreal injections are the standard treatment for retinopathy of prematurity (ROP). Schlemm's canal, essential for regulating the conventional aqueous humor outflow pathway, is still in development in premature infants. Anti-VEGF injections in premature infants may negatively impact Schlemm's canal development, potentially increasing glaucoma risk. We sought to determine the effects of anti-VEGF intravitreal injections on Schlemm's canal morphology in neonatal mice. We therefore assessed Schlemm's canal morphology following anti-VEGF intravitreal injections in neonatal mice subjected to the oxygen-induced retinopathy (OIR) model with features of ROP. Intraocular pressure (IOP) was measured 5 days following injections, and ex vivo analyses of retinal flatmounts and anterior eye cups were performed to assess retinal vasculature (isolectin B4) and Schlemm's canal morphology (CD31). Intravitreal injections of anti-VEGF antibody reduced both retinal vascular and avascular areas in OIR retinas compared to control. However, anti-VEGF injections did not induce changes in Schlemm's canal morphology or sustained changes in IOP. Our findings indicate that a single intravitreal injection of anti-VEGF does not significantly affect murine Schlemm's canal morphology or IOP. If anti-VEGF intravitreal injections predispose infants to glaucoma later in life, these results suggest it is unlikely due to direct effects on Schlemm's canal morphology during development.

Indexed as

Anti-VEGFGlaucomaIntraocular pressureOxygen-induced retinopathyRetinopathy of prematuritySchlemm’s canal

Identifiers

PMID42380457
PMCPMC13619443

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.